ACCELERATED PUBLICATION
Loss of OPA1 Perturbates the Mitochondrial Inner Membrane Structure and Integrity, Leading to Cytochrome c Release and Apoptosis*

Aurélien Olichon, Laurent Baricault, Nicole Gas, Emmanuelle Guillou, Annie Valette, Pascale BelenguerDagger, and Guy Lenaers

From the Laboratoire de Biologie Cellulaire et Moléculaire du Contrôle de la Prolifération, UMR 5088, and the Laboratoire de Biologie Moléculaire des Eucaryotes, IFR109, Université Paul Sabatier, Bât. 4R3-B1, 118 route de Narbonne, F-31062 Toulouse cedex 04, France

Received for publication, December 6, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

OPA1 encodes a large GTPase related to dynamins, anchored to the mitochondrial cristae inner membrane, facing the intermembrane space. OPA1 haplo-insufficiency is responsible for the most common form of autosomal dominant optic atrophy (ADOA, MIM165500), a neuropathy resulting from degeneration of the retinal ganglion cells and optic nerve atrophy. Here we show that down-regulation of OPA1 in HeLa cells using specific small interfering RNA (siRNA) leads to fragmentation of the mitochondrial network concomitantly to the dissipation of the mitochondrial membrane potential and to a drastic disorganization of the cristae. These events are followed by cytochrome c release and caspase-dependent apoptotic nuclear events. Similarly, in NIH-OVCAR-3 cells, the OPA1 siRNA induces mitochondrial fragmentation and apoptosis, the latter being inhibited by Bcl2 overexpression. These results suggest that OPA1 is a major organizer of the mitochondrial inner membrane from which the maintenance of the cristae integrity depends. As loss of OPA1 commits cells to apoptosis without any other stimulus, we propose that OPA1 is involved in the cytochrome c sequestration and might be a target for mitochondrial apoptotic effectors. Our results also suggest that abnormal apoptosis is a possible pathophysiological process leading to the retinal ganglion cells degeneration in ADOA patients.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Large GTPases from the dynamin family are involved in various processes related to membrane dynamic (6, 7). Two dynamin subfamilies are specifically involved in the mitochondrial network morphology. One comprises the Dnm1/Drp1 protein that is located on the cytoplasmic side of the outer mitochondrial membrane (OM)1 to control the network fission process (8, 9). The second one includes the intra-mitochondrial Mgm1p/Msp1/OPA1 protein, which is required for the maintenance of the mitochondrial structure and genome in yeasts (10-12). Localization of this dynamin in the different species remains controversial and so does its precise function on the mitochondrial membranes. Mgm1 has been first localized anchored to the OM facing the cytoplasm (12), then in the intermembrane space (IMS) associated to the inner membrane (IM) (13). Msp1 has been located in the matrix anchored to the IM (11). Finally OPA1 has been recently located to the IMS anchored on the cristae IM (1). We have previously shown that mutations in the OPA1 gene induce the most common form of autosomal dominant optic atrophy (2, 3) (ADOA, MIM165500) and affect the structure of the mitochondrial network in monocytes from ADOA patients (3). The possible function of OPA1 as a mechano-enzyme (14) or as a molecular switch (15) acting on the IM suggests that it might be involved in the structure and dynamic of the cristae (16) and therefore on mitochondrial activity. In metazoan vertebrates, cristae structures have a crucial role as they define intra-cristae volumes that segregate the majority of the cytochrome c (cyt c) from the IMS (17). In vitro, upon addition of the pro-apoptotic factor tBid on purified mitochondria, this pool of cyt c is released in the IMS by a major cristae remodeling process, which allows in vivo the extensive release of the cyt c in the cytoplasm to trigger apoptosis (18). To address OPA1 function on the mitochondrial membranes and gain insight into the pathophysiological mechanism of ADOA, we have analyzed the OPA1 knock-down in culture cells and found that it disrupts the mitochondrial IM structure and functional integrity and leads to cyt c release and apoptosis.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Antibodies-- OPA1 antibodies have been described previously (1). Commercial antibodies were from the sources indicated: anti-HSP60 (LK2, Sigma), anti-Actin (Chemicon), anti-cytochrome c (Santa Cruz), anti-cleaved PARP (Promega), Alexa-594 anti-rabbit IgG and Alexa-488 anti-mouse IgG (Molecular Probes), and anti-rabbit IgG-HRP and anti-mouse IgG-HRP (New England Biolabs).

Cell Culture, RNA Interference (siRNA), and Western Blots-- HeLa cells were cultured in DMEM, 10% fetal calf serum, 5% CO2. NIH-OVCAR-3 cells (19) were cultured in RPMI, 5% fetal calf serum, 5% CO2. siRNA experiments were carried out as described previously (20). The sequence of the region targeted by the OPA1-siRNA (Dharmacond Research), 5'-AAGTTATCAGTCTGAGCCAGGTT-3', corresponds to nucleotides 1810-1833 of OPA1 open reading frame (GenBankTM accession number AB011139) and is present in all OPA1 alternate splicing variants (21). Transfections of HeLa cells were performed with Oligofectamine® reagent (Invitrogen). Final concentration of the siRNA duplex in culture medium was 100 nM. Control experiments included treatments of cells with 100 µM z-VAD-fmk (Calbiochem) for 48 h or 5 µM CDDP (Sigma) for 24 h. To detect OPA1 and actin by Western blot, transfected cells were trypsinized, washed once in ice-cold PBS, and harvested. Equal amounts of cells were solubilized in 50 µl of Laemmeli sample buffer and boiled for 10 min. Samples were run on 8% polyacrylamide gels and transferred to nitrocellulose. Immunodetection (anti-OPA1: 1/300; anti-actin: 1/10000; IgG-HRP: 1/10,000) was carried out using ECL (Amersham Biosciences). PARP detection was performed according to the protocol from Promega (anti-PARP: 1/1000).

Microscopy and FACS Analysis-- Cells grown on glass coverslips were fixed in PBS, 3.7% paraformaldehyde (30 min, 4 °C), permeated in 100% methanol (1 min, -20 °C), then in PBS, 0.2% Triton X-100 (10 min, room temperature) and immunolabeled in PBS, 2% bovine serum albumin, using the following antibodies (HSP60: 1/100; cytochrome c: 1/100; Alexa-594 anti-rabbit IgG: 1/500; Alexa-488 anti-mouse IgG: 1/500) and stained with DAPI (0.1 µg/ml). To quantify phenotypes, cells were stained directly in the culture using 100 nM CMXros Mitotracker® Red (Molecular Probes) for 30 min, then fixed and DAPI-stained. To analyze the Delta Psi m, cells were incubated 20 min with 5 µg/ml JC-1 (Molecular Probes) in culture medium and observed by confocal microscopy. Fluorescence images were captured and processed using a Leica DMIRE-2 microscope or a LSM-410 Zeiss confocal microscope. For FACS analyses of the Delta Psi m, cells were removed from the culture dishes and then pelleted by low centrifugation, resuspended in culture medium with 50 nM TMRE (Molecular Probes) (22), and analyzed 15 min later by flow cytometry (FACS-Calibur, BD Biosciences) using the Cellquest software. Control experiments included treatment with 50 mM DNP (Sigma) for 60 min or 2 µM Oligomycin (Sigma) for 30 min or 0.1% Nonidet P-40 for 30 min. For transmission electron microscopy, cells were fixed for 2 h with 4% glutaraldehyde in sodium cacodylate buffer, post-fixed for 1 h with 1% osmium tetroxide, dehydrated, and embedded in Epon (EMS). Thin sections adsorbed onto nickel grids were stained with 1% uranyl acetate and 0.3% lead citrate and imaged in a JEOL-1200 EX electron microscope at 80 kV. Mitochondria surfaces were assessed with the Image Tools 3.0 software.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Loss of OPA1 Induces the Fragmentation of the Mitochondrial Network-- We have designed a specific human OPA1 siRNA that corresponds to a sequence situated downstream of the GTPase coding sequence and analyzed its effect in HeLa cells comparatively with a control scramble siRNA (Dharmacond Research). After transfection, cells were collected every day for 3 days and Western blots performed. The different forms of OPA1 (1, 21) were slightly affected at 24 h, declined at 48 h, and were almost not detectable at 72 h (Fig. 1a). In parallel, the mitochondrial morphology was monitored on cells stained with the Mitotracker® Red (Fig. 1b). 24 h after transfection of the OPA1 siRNA, cells retained a filamentous mitochondrial network as control cells (Fig. 1b, top left). At 48 h, when OPA1 levels started to decline, half of the cells showed a filamentous mitochondrial network and half showed a fragmented one (Fig. 1b, bottom left). At 72 h, when OPA1 levels were barely detectable, the filamentous phenotype had virtually disappeared to the benefit of the fragmented phenotype (60%), and of an additional phenotype (35%) that we described in Fig. 4. Fragmentation of the mitochondrial network induced by the loss of OPA1 was further visualized by immunofluorescence experiments using HSP60 antibodies and confocal microscopy three-dimensional reconstructions (Fig. 1c).


View larger version (67K):
[in this window]
[in a new window]
 
Fig. 1.   Loss of OPA1 induces fragmentation of the mitochondrial network. HeLa cells were transfected with either the scramble siRNA (control/-) or the OPA1 siRNA (+) and grown for 24, 48, and 72 h. a, OPA1 and actin detection by Western blot. b, analysis of Mitotracker® Red and DAPI staining by fluorescence microscopy. Top left, filamentous mitochondrial network; bottom left, punctuated mitochondrial network; right, percentages of both phenotypes in the cell population. c, three-dimensional confocal imaging of cells labeled with HSP60 antibody 72 h after transfection. Bar = 1 µm.

Loss of OPA1 Dissipates the Mitochondrial Membrane Potential-- As a correlation between the IM potential dissipation and the fragmentation of the mitochondrial network has been recently established (23), we checked the effect of OPA1 down-regulation on the mitochondrial membrane potential (Delta Psi m) using JC1 and TMRE dyes. 72 h after OPA1 siRNA transfection, fluorescence microscopy observations revealed that the fragmented cells were all devoid of the JC1 Delta Psi m-sensitive red fluorescence (Fig. 2a), as cells treated with the uncoupling drug DNP, and in deep contrast to cells treated with oligomycine, that increases the Delta Psi m and consequently the amount of red fluorescence. FACS analyses performed with TMRE dye revealed that the Delta Psi m in cells treated with the OPA1 siRNA was decreased to a level similar to that estimated for cells treated with the DNP drug and slightly higher than that observed for cells treated with the Nonidet P-40 detergent (Fig. 2b).


View larger version (56K):
[in this window]
[in a new window]
 
Fig. 2.   Loss of OPA1 induces mitochondrial membrane potential reduction. Delta Psi m was assessed 72 h after cell transfection with scramble siRNA (control) or OPA1 siRNA, or on cells treated with various drugs (oligomycin, DNP, or Nonidet P-40 (NP40)). a, confocal pictures of cells stained with JC-1 dye. b, FACS analyses of TMRE incorporation.

Electron Microscopy Observations Show Major Disruption of the Cristae Structures-- To gain insight on the possible function of OPA1 on the mitochondrial IM, we performed transmission electron microscopic observations on cells transfected or not by the OPA1 siRNA and grown for 72 h. Classical long tubular cylinders (mean mitochondrial surface area: 0.66 ± 0.49 µm2, n = 69) were observed in control cells (Fig. 3a), while circular vesicles of reduced diameter (0.115 ± 0.059 µm2, n = 194) predominated in treated cells (Fig. 3, b and c), confirming the photonic observations. Mitochondria from cells devoid of OPA1 further presented electron denser matrix and cristae completely unstructured, adopting unusual shapes consisting of vesicle-like structures with abnormal increased space between the membranes (Fig. 3, b, c, and b'), providing evidence suggesting that OPA1 has a major function in structuring the cristae membranes.


View larger version (180K):
[in this window]
[in a new window]
 
Fig. 3.   Loss of OPA1 causes a disorganization of the cristae structure. Electron microscopic micrographs of a thin section of HeLa cells showing the structure of mitochondria 72 h after transfection without (a) or with OPA1 siRNA (b, c). Drawing of two representative mitochondria are presented (a' and b').

Loss of OPA1 Triggers a Bcl2-inhibitable Apoptosis-- Our electron microscopy pictures are consistent with descriptions of mitochondrial pyknosis (24) and of the switch from wild-type to apoptotic mitochondria in liver cells (18). In addition, our previous photonic observations, revealed 72 h after transfection of the OPA1 siRNA a high proportion (35%) of cells, with aggregated mitochondria, condensed chromatin, and fractionated nucleus reminiscent to apoptotic phenotype (Fig. 4a). To assert apoptosis, we estimated the amounts of the cleaved PARP protein (25) by Western blot (Fig. 4a) and found that they correlated with the percentage of apoptotic cells. PARP cleavage did not occur in the presence of the caspases inhibitor z-VAD-fmk, but well in cells treated with CDDP (Fig. 4a). Cytochrome c release was further monitored by immunofluorescence using cyt c antibodies 72 h after the OPA1 siRNA transfection. Barely half of the cell population had released cyt c in the cytoplasm (Fig. 4b), while no cyt c release or apoptotic figure was observed in control cells. To address the issue whether the anti-apoptotic Bcl2 protein could counteract the OPA1 induced apoptotic process, the OPA1 and scramble siRNA were transfected in an ovarian adenocarcinoma cell line (NIH-OVCAR-3) expressing constitutively or not Bcl2 (19) (Fig. 5d). Loss of OPA1 (Fig. 5d) triggered fragmentation of the mitochondrial network in both cell lines (Fig. 5, a and b), while no morphological change was found using the scramble siRNA. In addition, 72 h after transfection, apoptosis (Fig. 5c) reached 27% in the OVCAR cells, but was reduced by a 3-fold ratio in cells overexpressing Bcl2 (Fig. 5d). Thus, in a second transformed cell line, loss of OPA1 triggers fragmentation of the mitochondrial network and an apoptotic process that can be inhibited by Bcl2 overexpression.


View larger version (52K):
[in this window]
[in a new window]
 
Fig. 4.   Loss of OPA1 triggers apoptosis. a, kinetic of appearance of the apoptotic phenotype in cells transfected with the scramble (-) or the OPA1 (+) siRNA stained with DAPI and Mitotracker® Red. A Western blot detecting the PARP-cleaved form (PARP p89) and actin, 24, 48, and 72 h after transfection. As control, OPA1 siRNA-transfected cells were treated with z-VAD-fmk, or untransfected cells were treated with CDDP. b, fluorescence microscopy using DAPI and Mitotracker® Red or cytochrome c antibodies on cells, 72 h after transfection with scramble (control) or OPA1 siRNA.


View larger version (57K):
[in this window]
[in a new window]
 
Fig. 5.   Apoptosis induced by the OPA1 siRNA is inhibited by Bcl-2 in NIH-OVCAR-3 cells. NIH-OVCAR-3 cells expressing constitutively (Bcl2) or not (Neo) Bcl2 were transfected with the scramble (control) or the OPA1 siRNA. a-c, pictures showing the filamentous (a), punctuated (b), and apoptotic (c) phenotypes of the OVCAR-Neo cells stained with Mitotracker® Red and DAPI. d, percentage of apoptotis and Western blots revealing OPA1, actin, and Bcl2 in both cell lines, 72 h after transfection.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Results presented here have shown that loss of OPA1 induces structural and functional modifications of the mitochondria. Indeed, down-regulation of OPA1 expression changes the mitochondrial network fusion-fission balance toward fission, as already noticed for its orthologs Mgm1p (13) and Msp1 2 in yeast. Thus OPA1 could either contributes as a fusion effector or as a fission inhibitor. Alternatively, the fragmentation of the mitochondrial network could be the consequence of the dissipation of the IM potential induced by loss of OPA1. In this respect, we further observed that the cristae were completely disorganized in the absence of OPA1. This later phenomenon could be the central process that would first dissipate the IM potential, then open the cristae junctions, allowing mobilization of cyt c and its release in the cytoplasm to trigger caspase-dependent apoptosis. How in this situation the cyt c crosses the OM remains unclear, but this process and the downstream apoptotic events are inhibited by the overexpression of Bcl2. These data converge to propose that OPA1 participates in structuring the cristae to maintain their functional integrity. Therefore, OPA1 might be a key protein that modulates the IM dynamic to either maintain cell homeostasis or commit them to apoptosis and, consequently, could be a target for pro- or anti-apoptotic effectors. Thus coordinate structural changes of both mitochondrial membranes during apoptosis could be performed by both families of mitochondrial dynamin, as Drp1 was recently shown to be involved in the fragmentation of the mitochondrial network during apoptosis (26).

Finally, the link between OPA1 and apoptosis gives clues on the possible pathophysiological effect of mutations in the OPA1 gene found in ADOA patients that leads to the neurodegeneration of the retinal ganglion cells (5). Indeed, this cell population undergoes two rounds of apoptotic process during normal life: one during development when setting up the retina, which eliminates 70% of them, and one during every day life, which accounts for a loss of few thousands of them per year (27). Haplo-insufficiency generated by the dysfunction of one OPA1 allele (4) might increase their susceptibility to apoptogen stimuli and in particular the one generated by the daily exposure to the UV light.

    ACKNOWLEDGEMENTS

We are indebted to the IFR109 technical resources and Brice Roncin for help in electron and confocal microscopy and members of the UMR5088 for helpful discussions.

    FOOTNOTES

* This work was supported by grants from the Centre National pour la Recherche Scientifique, Université Paul Sabatier, Ministère de la Recherche et de l'Education, Rétina France, Fondation pour la Recherche Médicale, Association pour la Recherche sur le Cancer, Fondation Electricité de France, and l'Association Française contre les Myopathies.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed. Tel.: 33-561-55-62-38; Fax: 33-561-55-81-09; E-mail: belengue@cict.fr.

Published, JBC Papers in Press, December 31, 2002, DOI 10.1074/jbc.C200677200

2 E. Guillou, unpublished data.

    ABBREVIATIONS

The abbreviations used are: OM, outer mitochondrial membrane; IM, inner mitochondrial membrane; IMS, intermembrane space; cyt c, cytochrome c; HRP, horseradish peroxidase; z-VAD-fmk, z-Val-Ala-Asp-fluoromethylketone; CDDP, cis-diamine dichloroplatinum; PBS, phosphate-buffered saline; PARP, poly(ADP-ribose) polymerase; FACS, fluorescence-activated cell sorter; DAPI, 4',6-diamidino-2-phenylindole; TMRE, tetramethyl rhodamine ethyl ester; DNP, dinitrophenol; siRNA, small interfering RNA.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Olichon, A., Emorine, L. J., Descoins, E., Pelloquin, L., Brichese, L., Gas, N., Guillou, E., Delettre, C., Valette, A., Hamel, C. P., Ducommun, B., Lenaers, G., and Belenguer, P. (2002) FEBS Lett. 523, 171-176[CrossRef][Medline] [Order article via Infotrieve]
2. Alexander, C., Votruba, M., Pesch, U. E., Thiselton, D. L., Mayer, S., Moore, A., Rodriguez, M., Kellner, U., Leo-Kottler, B., Auburger, G., Bhattacharya, S. S., and Wissinger, B. (2000) Nat. Genet. 26, 211-215[CrossRef][Medline] [Order article via Infotrieve]
3. Delettre, C., Lenaers, G., Griffoin, J. M., Gigarel, N., Lorenzo, C., Belenguer, P., Pelloquin, L., Grosgeorge, J., Turc-Carel, C., Perret, E., Astarie- Dequeker, C., Lasquellec, L., Arnaud, B., Ducommun, B., Kaplan, J., and Hamel, C. P. (2000) Nat. Genet. 26, 207-210[CrossRef][Medline] [Order article via Infotrieve]
4. Thiselton, D. L., Alexander, C., Taanman, J. W., Brooks, S., Rosenberg, T., Eiberg, H., Andreasson, S., Van Regemorter, N., Munier, F. L., Moore, A. T., Bhattacharya, S. S., and Votruba, M. (2002) Invest. Ophthalmol. Vis. Sci. 43, 1715-1724[Abstract/Free Full Text]
5. Kjer, P., Jensen, O. A., and Klinken, L. (1983) Acta Ophthalmol. (Copenh.) 61, 300-312[Medline] [Order article via Infotrieve]
6. Danino, D., and Hinshaw, J. E. (2001) Curr. Opin. Cell Biol. 13, 454-460[CrossRef][Medline] [Order article via Infotrieve]
7. van der Bliek, A. M. (1999) Trends Cell Biol. 9, 96-102[CrossRef][Medline] [Order article via Infotrieve]
8. Bleazard, W., McCaffery, J. M., King, E. J., Bale, S., Mozdy, A., Tieu, Q., Nunnari, J., and Shaw, J. M. (1999) Nat. Cell Biol. 1, 298-304[CrossRef][Medline] [Order article via Infotrieve]
9. Smirnova, E., Shurland, D. L., Ryazantsev, S. N., and van der Bliek, A. M. (1998) J. Cell Biol. 143, 351-358[Abstract/Free Full Text]
10. Jones, B. A., and Fangman, W. L. (1992) Genes Dev. 6, 380-389[Abstract]
11. Pelloquin, L., Belenguer, P., Menon, Y., Gas, N., and Ducommun, B. (1999) J. Cell Sci. 112, 4151-4161[Abstract/Free Full Text]
12. Shepard, K. A., and Yaffe, M. P. (1999) J. Cell Biol. 144, 711-720[Abstract/Free Full Text]
13. Wong, E. D., Wagner, J. A., Gorsich, S. W., McCaffery, J. M., Shaw, J. M., and Nunnari, J. (2000) J. Cell Biol. 151, 341-352[Abstract/Free Full Text]
14. Stowell, M. H., Marks, B., Wigge, P., and McMahon, H. T. (1999) Nat. Cell Biol. 1, 27-32[CrossRef][Medline] [Order article via Infotrieve]
15. Sever, S., Damke, H., and Schmid, S. L. (2000) Traffic 1, 385-392[CrossRef][Medline] [Order article via Infotrieve]
16. Mannella, C. A., Pfeiffer, D. R., Bradshaw, P. C., Moraru, I. I., Slepchenko, B., Loew, L. M., Hsieh, C. E., Buttle, K., and Marko, M. (2001) Dig. Liver Dis. 33, 795-802[CrossRef][Medline] [Order article via Infotrieve]
17. Bernardi, P., and Azzone, G. F. (1981) J. Biol. Chem. 256, 7187-7192[Abstract/Free Full Text]
18. Scorrano, L., Ashiya, M., Buttle, K., Weiler, S., Oakes, S. A., Mannella, C. A., and Korsmeyer, S. J. (2002) Dev. Cell 2, 55-67[CrossRef][Medline] [Order article via Infotrieve]
19. Lafon, C., Mathieu, C., Guerrin, M., Pierre, O., Vidal, S., and Valette, A. (1996) Cell Growth Differ. 7, 1095-1104[Abstract]
20. Elbashir, S. M., Harborth, J., Weber, K., and Tuschl, T. (2002) Methods 26, 199-213[CrossRef][Medline] [Order article via Infotrieve]
21. Delettre, C., Griffoin, J. M., Kaplan, J., Dollfus, H., Lorenz, B., Faivre, L., Lenaers, G., Belenguer, P., and Hamel, C. P. (2001) Hum. Genet. 109, 584-591[CrossRef][Medline] [Order article via Infotrieve]
22. Castedo, M., Ferri, K., Roumier, T., Metivier, D., Zamzami, N., and Kroemer, G. (2002) J. Immunol. Methods 265, 39-47[CrossRef][Medline] [Order article via Infotrieve]
23. Legros, F., Lombes, A., Frachon, P., and Rojo, M. (2002) Mol. Biol. Cell 13, 4343-4354[Abstract/Free Full Text]
24. Desagher, S., and Martinou, J. C. (2000) Trends Cell Biol. 10, 369-377[CrossRef][Medline] [Order article via Infotrieve]
25. Sallmann, F. R., Bourassa, S., Saint-Cyr, J., and Poirier, G. G. (1997) Biochem. Cell Biol. 75, 451-456[CrossRef][Medline] [Order article via Infotrieve]
26. Frank, S., Gaume, B., Bergmann-Leitner, E. S., Leitner, W. W., Robert, E. G., Catez, F., Smith, C. L., and Youle, R. J. (2001) Dev. Cell 1, 515-525[Medline] [Order article via Infotrieve]
27. Farkas, R. H., and Grosskreutz, C. L. (2002) Ophthalmol. Clin. North Am. 15, 61-68[Medline] [Order article via Infotrieve]


Copyright © 2003 by The American Society for Biochemistry and Molecular Biology, Inc.